Purpose The purpose of this study is to investigate the clinical significance of tyrosine hydroxylase (TH) expression in peripheral blood (PB) at diagnosis in patients with neuroblastoma.
Introduction
Neuroblastoma (NB) is a common childhood solid tumor that presents with clinical heterogeneity. The presentation of NB can range from localized tumors to disseminated forms, which have different prognoses and require different treatment [1, 2] . Therefore, determining the disease extent and stage at the time of diagnosis is important. A number of genetic and biological markers have been investigated for detection of minimal levels of NB cells [3] . Tyrosine hydroxylase (TH), which is mainly expressed in sympathetic nervous tissues [4] , has been suggested as a candidate marker for detecting minimal levels of neuroblastoma cells in bone marrow (BM) and peripheral blood (PB) [5] . Molecular detection of TH mRNA using reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) has been proposed as a specific and sensitive method for detection of [5] [6] [7] [8] .
According to our preliminary reports, positive TH expression in PB at diagnosis is a poor prognostic factor [9] . However, the number of patients was small and the followup duration was short. In the current study, we evaluated the significance of TH expression in a larger cohort of patients with a longer follow-up period as well as the clinical implications of the level of TH expression among TH-positive patients.
Materials and Methods
Written informed consent for TH analysis was obtained at diagnosis from all patients or guardians. This retrospective study was approved by the Institutional Review Board (IRB) of Samsung Medical Center and the requirement for informed consent was waived (IRB 2014-12-090).
Patients
Medical records of all patients who were newly diagnosed with NB over a 10-year period from July 2005 to June 2015 were reviewed retrospectively. Patients were staged according to the International Neuroblastoma Staging System [10] and disease extent was evaluated using computerized tomography (CT), magnetic resonance imaging (MRI), technetium-99 bone scans, bilateral BM aspirates and biopsy specimens, and 131 I-or 123 I-metaiodobenzylguanidine (MIBG) scanning. Measurement of TH expression in PB was included in routine evaluation at diagnosis. MYCN amplification was determined using competitive polymerase chain reaction (PCR), RT-qPCR, or fluorescence in situ hybridization. Tumors were classified as histologically favorable or unfavorable according to the International Neuroblastoma Pathology Classification [11] . Measurement of serum lactic dehydrogenase (LDH), ferritin, neuron-specific enolase (NSE), and urine vanillylmandelic acid (VMA) was also included in routine evaluation at diagnosis. 
Treatment
Excisional biopsy of the primary tumor was performed at diagnosis for resectable tumors. Otherwise, incisional or percutaneous needle biopsy was performed with definitive surgery after six chemotherapy cycles. Alternating CEDC (cisplatin+etoposide+doxorubicin+cyclophosphamide) and ICE (ifosfamide+carboplatin+etoposide) regimens were used for chemotherapy (Table 1 Local radiotherapy was applied to the primary site in all high-risk patients approximately 6 weeks after the second HDCT/auto-SCT. Differentiation therapy involving 13-cis-retinoic acid with immunotherapy using interleukin 2 (210 6 U/m 2 /day for 5 days every 4 weeks) was administered until 1 year after HDCT/auto-SCT to reduce relapse from minimal residual tumor cells [12] .
RT-qPCR for TH expression analysis
PB samples were collected at diagnosis in ethylenediaminetetraacetic acid tubes and mononuclear cells were separated and lysed in TRIzol reagent (Invitrogen Corporation, Carlsbad, CA). RNA was extracted according to the manufacturer's instructions and 1 g of RNA was used to generate 20 L of complementary DNA using an RNA PCR kit (Applied Biosystems, Foster City, CA). RT-qPCR was performed using Real-Q TH Quantification Kits (BioSewoom, Seoul, Korea) on a LightCycler (Roche Diagnostics, Mannheim, Germany). RT-qPCR was performed under the following cycling conditions: denaturation at 95°C for 10 minutes, 45 cycles at 95°C for 10 seconds, 60°C for 10 seconds, and 72°C for 30 seconds, followed by a cooling step at 40°C for 30 seconds. Reactions were performed in a 20-L volume containing PCR reaction mixture, TaqMan probe (5'-FAM AGCGCAGGAAGCTGATTGCTGAGTAMRA-3'), primer mixture (forward, 5'-TCATCACCTGGTCACCAAGTT -3'; reverse, 5'-GGTCGCCGTGCCTGTACT-3'), 2 L cDNA, and sterile water. The ABL gene was used as a control gene in RT-qPCR. If the expression value of ABL in the RT-qPCR amplification was less than a copy number of 104, the sample was considered inadequate for RT-qPCR analysis and the RNA extraction was repeated. The quantity of TH transcripts was normalized to the ABL transcript level, and the result was expressed as the ratio of the TH to ABL transcript copy number.
Statistics
Pearson's chi-squared test was used for comparison of frequencies between groups. The Mann-Whitney U test was used for comparison of continuous variables between groups. Progression-free survival (PFS) and overall survival (OS) rates with standard errors were estimated using the Kaplan-Meier method. Relapse was regarded as progression in the statistical analysis. Differences in PFS rates between groups were compared using the log-rank test. Multivariate analyses of prognostic factors for PFS and OS were performed using Cox regression analysis. p-values less than 0.05 were considered significant.
Results

Patient characteristics
A total of 210 patients (118 boys and 92 girls) were evaluated for the presence of TH mRNA in PB at diagnosis. The clinical and biological characteristics of patients are shown in Table 2 . The median age at diagnosis was 22 months (range, 0 to 232 months) and median follow-up duration was 51 months (range, 1 to 122 months). At diagnosis, 134 patients were older than 12 months, 103 patients had metastatic tumors including four stage 4S tumors, 90 had histologically unfavorable tumors, and 34 had MYCN amplified tumors. Among 89 patients with high-risk tumors, 30 patients used TM-TBI regimen in the second HDCT/ auto-SCT and the remaining 59 patients used 131 I-MIBG-TM regimen.
RT-qPCR analysis of TH expression in PB
TH expression was positive in PB at diagnosis in 60 of 210 patients (28.6%). The median expression level (TH/ABL ratio) of TH mRNA transcript detected in PB was 1,58010 -6 (range, 210 -6 to 3,711,86410 -6 ). Positive TH expression was associated with high-risk features (i.e., advanced stage, older age, unfavorable pathology, and MYCN amplification). The levels of serum LDH, ferritin, NSE, and urine VMA were also higher in TH-positive patients (Table 2) . Among 60 TH-positive patients, 50 had metastatic tumors and the remaining 10 had localized tumors (stage 1 in three, stage 2 in two, and stage 3 in five patients). Among the TH-positive patients, a higher TH expression level was associated with advanced stage and high-risk tumor, but not with older age ( 12 months) or MYCN amplification (Fig. 1A-D) .
Survival according to TH expression at diagnosis
Relapse or progression occurred in 19 of 60 TH-positive patients (31.7%), compared with only six of 150 TH-negative patients (4.0%). Lower 5-year probabilities of PFS and OS were observed in TH-positive patients than in TH-negative patients (PFS: 63.8±6.9% vs. 94.7±2.1%, p < 0.001; OS: 70.2± 6.7% vs. 92.4±2.5%, p < 0.001) (Fig. 2A) . In analysis confined to only high-risk patients, the 5-year probabilities of PFS and OS remained lower in TH-positive patients (PFS: 55.7±8.2% vs. 89.6±5.8%, p=0.001; OS: 61.4±8.1% vs. 87.2±6.1%, p=0.064) (Fig. 2B) . However, in low-and intermediate-risk patients, no difference in the 5-year probabilities of PFS and OS was observed between TH-positive patients and TH-negative Table 3 . Positive TH expression in PB at diagnosis was an independent factor for PFS (hazard ratio, 6.35; 95% confidence interval, 2.10 to 19.25; p=0.001). The results were similar when the analysis was confined to high-risk patients (hazard ratio, 9.02; 95% confidence interval, 2.06 to 39.50; p=0.004) ( Table 4 ). Among TH-positive patients, a higher expression level of TH was associated with a worse outcome (above median level vs. below median level: 52.9± 10.0% vs. 75.7±8.8%, p=0.075 for 5-year PFS; 55.9±9.6% vs. 89.2±5.9%, p=0.047 for 5-year OS) (Fig. 2C) . 
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Discussion
A number of genetic markers have been investigated for detection of minimal levels of NB cells [13] [14] [15] [16] [17] . Viprey et al. [18] reported that the TH, DCX, and PHOX2B genes are the best candidates for detection of circulating NB cells. Corrias et al. [19] , who investigated the advantages of measuring multiple molecular targets over a single molecular target, reported that combinations of multiple targets did not add to the predictive power of TH analysis alone. Gilbert et al. [20] also reported that TH might be the one of the most useful molecular targets. In this context, in the current study we measured TH mRNA alone for molecular detection of mini- mal disease in all patients who were newly diagnosed with NB.
Positive TH expression in PB at diagnosis was associated with high-risk features and worse outcome. More importantly, positive TH expression in PB at diagnosis was an independent poor prognostic factor for PFS. The results were similar when the analysis was confined to high-risk patients. Current staging systems use conventional diagnostic modalities such as CT, MRI, BM biopsy, and various radioisotope scans. Patients are stratified into risk groups based on these staging systems and patients within each risk group are treated uniformly. However, our study showed that outcomes within the high-risk group differ according to TH expression in PB at diagnosis. Previous studies also reported that positive TH expression was a poor prognostic indicator in metastatic NB [13, 21, 22] . These findings suggest that TH expression at diagnosis might be a significant factor in future methods of risk stratification for NB. Some studies examined the clinical implication of positive TH expression in non-metastatic NB [19, 23] . Yanez et al. [23] reported an association of positive TH expression in PB at diagnosis with a higher probability of relapse in patients with non-metastatic NB. These findings suggest that some patients with localized tumors (by conventional diagnostic modalities) might have disseminated micrometastatic disease and therefore might benefit from upstaging and more aggressive treatment [24] . However, in the current study, because only one of 10 TH-positive patients with localized tumor experienced relapse, the significance of TH expression in patients with localized tumors was unclear. Further studies including more patients are needed to evaluate the prognostic importance of TH expression in the PB of patients with localized tumors.
Among TH-positive patients, higher TH expression was associated with advanced stage and high-risk tumor, but not with older age or MYCN amplification, and a higher TH expression level at diagnosis was associated with a worse outcome. Yanez et al. [25] reported that a high level of TH mRNA in PB was a significant independent predictor of event-free survival and OS when detected at diagnosis, postinduction therapy, and at the end of treatment. They proposed inclusion of TH mRNA monitoring throughout the disease course by RT-qPCR as a standard method of disease evaluation that would be helpful in predicting differences in outcome and identify children for whom current treatment is failing or insufficient [25] . The European HR-NBL1/ SIOPEN study defined patients with very high TH expression as ultrahigh-risk. These ultrahigh-risk patients showed very poor outcome among the group of high-risk NB patients (PFS, 0%), most of whom underwent single HDCT/auto-SCT Na Hee Lee, TH Expression in PB in Neuroblastoma PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; PB, peripheral blood; TH, tyrosine hydroxylase.
following short induction treatment. The authors suggested that patients with very high TH expression are candidates for alternative treatment strategies [22] . In the current study, the prognosis of patients with high TH expression was also poorer than for those with low TH expression, but was not dismal. The relatively better outcome in our patients with high TH expression compared to those in the European HR-NBL1/SIOPEN study might be attributable to the longer induction treatment and more intensive consolidation treatment using tandem HDCT/auto-SCT.
Conclusion
In conclusion, positive TH expression in PB at diagnosis of neuroblastoma is associated with high-risk features and is an independent prognostic factor for poor PFS. Results of the current study suggest that treatment intensity should be tailored according to TH expression in PB at diagnosis.
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